Patent ID: 7465703

Claim:
A method for guiding administration of a therapeutic agent in a subject afflicted with osteoporosis, comprising: a) obtaining a first biological sample from the subject; b) administering to said subject a parathyroid hormone (PTH) based therapeutic composition comprising PTH1-84 or PTH1-34; c) obtaining a second biological sample from said subject after administration of said therapeutic; and d) evaluating said first and second samples for a PTH antagonist level, and optionally a total PTH level or a PTH1-84 level, wherein the PTH antagonist is PTH7-84, wherein if the PTH antagonist is present at a higher level in the second sample versus the first sample, and/or if the ratio of the PTH antagonist versus the total PTH level or the PTH1-84 level is higher in the second sample versus the first sample, then the subject may be considered a candidate for treatment with said PTH based therapeutic composition, and wherein, if the PTH antagonist is present at the same or lower level in the second sample versus the first sample, and/or if the ratio of the PTH antagonist level versus total PTH level or the PTH1-84 level is the same or lower in the second sample versus the first sample, then the subject is not considered a candidate for treatment with said PTH based therapeutic composition.